Abstract
In the human brain several cell types are capable of initiating and amplifying a brain specific inflammatory response involving the synthesis of cytokines, prostaglandins and oxygen free radicals. In Alzheimers disease (AD), signs of an inflammatory activation of microglia and astroglia are present inside and outside amyloid deposits. Cell culture and animal models suggest an interactive relationship between inflammatory activation, reduced neuronal functioning and deposition of amyloid. The activation of inflammation-associated enzymes such as p38 mitogen-activated protein kinase (p38 MAPK) and cycloxygenase-2 (COX-2) is not restricted to glial cells but also found in neurons and may contribute to intraneuronal damage. Epidemiological studies have shown a reduced risk of AD among users of anti-inflammatory drugs. Therefore, anti-inflammatory drugs have become the focus of several new treatment strategies. Small clinical trials with non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin and diclofenac showed a trend for a disease modifying effect, while clinical trials with steroids did not show a beneficial effect. NSAIDs may not only act on COX-2 but also inhibit COX-1 activity or activate peroxisome proliferator-activated receptor gamma (PPARγ. Among promising new strategies to reduce the inflammatory activation in the CNS interfering with intracellular pro-inflammatory pathways has been shown to be effective in various cell culture and animal models. Inhibitors of p38MAPK and PPARγ agonists may be suitable agents to suppress inflammatory activation in AD.
Keywords: Alzheimers Disease, Microglia, Astroglia, p38 mitogen-activated protein kinase (p38 MAPK), cycloxygenase-2 (COX-2), non-steroidal anti-inflammatory drugs (NSAIDs), peroxisome proliferator-activated receptor, anti-inflammatory drugs
Current Medicinal Chemistry
Title: Pathways of Inflammatory Activation in Alzheimers Disease: Potential Targets for Disease Modifying Drugs
Volume: 9 Issue: 1
Author(s): M. Hull, K. Lieb and B. L. Fiebich
Affiliation:
Keywords: Alzheimers Disease, Microglia, Astroglia, p38 mitogen-activated protein kinase (p38 MAPK), cycloxygenase-2 (COX-2), non-steroidal anti-inflammatory drugs (NSAIDs), peroxisome proliferator-activated receptor, anti-inflammatory drugs
Abstract: In the human brain several cell types are capable of initiating and amplifying a brain specific inflammatory response involving the synthesis of cytokines, prostaglandins and oxygen free radicals. In Alzheimers disease (AD), signs of an inflammatory activation of microglia and astroglia are present inside and outside amyloid deposits. Cell culture and animal models suggest an interactive relationship between inflammatory activation, reduced neuronal functioning and deposition of amyloid. The activation of inflammation-associated enzymes such as p38 mitogen-activated protein kinase (p38 MAPK) and cycloxygenase-2 (COX-2) is not restricted to glial cells but also found in neurons and may contribute to intraneuronal damage. Epidemiological studies have shown a reduced risk of AD among users of anti-inflammatory drugs. Therefore, anti-inflammatory drugs have become the focus of several new treatment strategies. Small clinical trials with non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin and diclofenac showed a trend for a disease modifying effect, while clinical trials with steroids did not show a beneficial effect. NSAIDs may not only act on COX-2 but also inhibit COX-1 activity or activate peroxisome proliferator-activated receptor gamma (PPARγ. Among promising new strategies to reduce the inflammatory activation in the CNS interfering with intracellular pro-inflammatory pathways has been shown to be effective in various cell culture and animal models. Inhibitors of p38MAPK and PPARγ agonists may be suitable agents to suppress inflammatory activation in AD.
Export Options
About this article
Cite this article as:
Hull M., Lieb K. and Fiebich L. B., Pathways of Inflammatory Activation in Alzheimers Disease: Potential Targets for Disease Modifying Drugs, Current Medicinal Chemistry 2002; 9 (1) . https://dx.doi.org/10.2174/0929867023371292
DOI https://dx.doi.org/10.2174/0929867023371292 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Vaccination Against the H1N1 Virus on BDNF and TNF-α Plasma Levels in Pregnant Women
Current Drug Safety Beta-Adrenoreceptor Modulation of Metabolic, Endocrine and Immunologic Function During Critical Illness
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemokines as Natural HIV Antagonists
Current Molecular Medicine Allergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Current Pediatric Reviews Chondroitin Sulfate and Sulfur Containing Chondroprotective Agents: Is there a Basis for their Pharmacological Action?
Current Rheumatology Reviews In Vitro and In Vivo Evaluation of DMSO and Azone as Penetration Enhancers for Cutaneous Application of Celecoxib
Current Drug Delivery ACKNOWLEDGEMENTS TO CONTRIBUTORS (2015):
Recent Patents on Inflammation & Allergy Drug Discovery Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling
Current Drug Targets Editorial [Hot Topic: Role of Inflammation in the Evolution of Cancer Disease (Guest Editor: Antonio Maccio)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Phosphatidylinositol 3-kinase Glu545Lys and His1047Tyr Mutations are not Associated with T2D
Current Diabetes Reviews Intracellular Redox State as Target for Anti-Influenza Therapy: Are Antioxidants Always Effective?
Current Topics in Medicinal Chemistry Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
Current Pharmaceutical Biotechnology Major Drugs Used in COVID-19 Treatment: Molecular Mechanisms, Validation and Current Progress in Trials
Coronaviruses Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments
Current Medicinal Chemistry Editorial: Anti-Infective Drug Discovery Based on Diversified Plant Natural Compounds
Current Organic Chemistry Preface
Current Enzyme Inhibition CD8+ T-cells: Are They Sufficient to Prevent, Contain or Eradicate HIV-1 Infection?
Current Drug Targets - Infectious Disorders Death Receptors as Targets of Cancer Therapeutics
Current Cancer Drug Targets 1, 2, 4-Oxadiazole Incorporated Ketoprofen Analogues in Search of Safer Non-steroidal Anti-inflammatory Agents: Design, Syntheses, Biological Evaluation and Molecular Docking Studies
Letters in Drug Design & Discovery The Curcumin and Gingerol Combination as an Immune Regulator and Anti-Inflammatory Agent of SARS-CoV Infection According to a Nutrigenomic Approach: A Mini-Review
The Natural Products Journal